Skip to main content

Vascepa, A Prescription Omega-3 Fatty Acid, Shows Heart Health Benefits in High-Risk Populations

By Divya Gopisetty, Martin Kurian, Jimmy McDermott, and Maeve Serino

Amarin’s Vascepa, an omega-3 fatty acid, shown to lower risk of heart attack, stroke, and heart-related death for adults with high risk for heart disease with elevated triglycerides

Editor's note: this piece was updated on 11/13/18 to reflect the data presented at the 2018 AHA Scientific Sessions in Chicago. This piece was updated on 11/15/19 after the FDA Advisory Committee vote.

Amarin, a Dublin, Ireland-based company, has announced positive results from its REDUCE-IT trial testing Vascepa, a prescription omega-3 fatty acid, in adults on statins with heart disease or diabetes and other risk factors for heart disease.

Data presented at the 2018 American Heart Association (AHA) conference in Chicago showed that Vascepa resulted in an overall reduction in important heart-related events by 25%, including:

  • 20% reduction in death due to heart related causes

  • 31% reduction in heart attack

  • 28% reduction in stroke

The study followed 8,179 participants for nearly five years. Almost 58 percent of the trial participants had type 2 diabetes. On November 14, 2019, considering this data from REDUCE-IT, an FDA Advisory Committee voted 16-0 in favor of approving Vascepa for heart disease. It is not yet clear whether the approval will be for people with diabetes and other risk factors of heart disease (primary prevention) or limited to people with existing heart disease (secondary prevention). 

A primary prevention label would be a huge win for people with diabetes and would open up Vascepa to millions more people with diabetes and heart disease risk factors. We expect to hear a decision by December 28th, 2019. 

Vascepa is an FDA-approved therapy for people with very high levels (greater than 500 mg/dl) of triglycerides, which are a type of body fat. For most people in the US with private, Medicaid, or Medicare insurance, Vascepa costs about $3-6 per month with a co-pay card.

Vascepa is an omega 3 fatty acid, similar to those found in a fish oil supplement. However, unlinke Vascepa, fish oil supplements generally contain two kinds of omega-3 fatty acids, EPA and DHA. There have been many clinical trials, such as the ASCEND trial, that have failed to find any heart health benefit from fish oil in people with diabetes. But, these supplements included DHA, which is thought to potentially elevate LDL, the type of cholesterol traditionally associated with worse health outcomes. Vascepa contains a much larger dose of EPA than typical fish oil products. In the ASCEND trial, participants were also at low risk for heart disease and were taking a low-dose of just 1 gram per day.

In contrast, the REDUCE-IT trial studied a high-risk population and prescribed a higher dose of 4 grams per day. In addition, Vascepa only contains EPA. These might be the reasons this trial showed more positive outcomes. The REDUCE-IT trial studied over 8,000 adults with very high triglyceride levels and statin-controlled LDL cholesterol between 41-100 mg/dl (ADA’s recommended goal for people with diabetes is below 100 mg/dl). Overall, the most commonly reported side effect of Vascepa was joint pain (arthralgia). The press release also notes that the safety profile was similar to other study data on omega-3 fatty acids. 

As people with both type 1 and type 2 diabetes are at increased risk of heart disease, this research around heart-protective therapies is promising. As a relatively low-cost drug, Vascepa may have the potential to help a wide range of people with diabetes and high triglycerides. One thing to note is that individuals on Vascepa will likely be required to take a total of four capsules per day – two capsules, twice a day.

Share this article